

PROGRAM AT A GLANCE



Plenary & Keynote



Meet The Expert



Symposium



Special Session



Oral Presentation

Day 1: Friday, 22 October 2021

Time	Virtual Auditorium 1	Virtual Auditorium 2	Virtual Auditorium 3
8.25am	<p>Opening Ceremony</p> <p>Welcome Address: Gavin S. Dawe Chairman, Organising Committee, AsCNP 2021</p>		
8.30am – 9.30am	<p style="text-align: center;">Plenary 1</p> <p style="text-align: center;">Challenges in the Treatment of Bipolar Disorders: Looking Ahead</p> <p>Lakshmi Yatham, Canada</p> <p><i>Chairperson:</i> <i>Chay Hoon Tan, Singapore</i></p>		
9.30am – 11:00am	<p style="text-align: center;">Meet The Expert 1 (USA)</p> <p style="text-align: center;">Advances in the understanding and management of treatment resistance in schizophrenia: Practical considerations</p> <p>John Kane, USA</p> <p><i>Chairperson:</i> <i>Jimmy Lee, Singapore</i></p>	<p style="text-align: center;">Symposium 1</p> <p style="text-align: center;">New treatment modalities in neuropsychiatric disorders</p> <p>Novels treatments in Huntington's disease and frontotemporal dementia - an Australian perspective Dennis Velakoulis, Australia</p> <p>Neuropsychiatric Aspects of Niemann Pick Type C Disease in Adults Mark Walterfang, Australia</p> <p>Advances in pharmacological treatments of Alzheimer's Dementia and Fronto-Temporal Dementia Simon Ducharme, Canada</p> <p><i>Chairperson:</i> <i>Cyrus Ho</i></p>	<p style="text-align: center;">Symposium 10</p> <p style="text-align: center;">The effects of Covid-19 pandemic on the treatment of mental disorders</p> <p>The impact of COVID-19 on the treatment model of mental disorders Li Yi, China</p> <p>Mental health outcomes among patients exposed to COVID-19 : Experience from Fangcang shelter hospital Guangyin Zhang, China</p> <p>Lessons Learned from Covid-19 Pandemic: Indonesia's Perspective Andi J Tanra, Indonesia</p> <p>Health Care Worker Wellness During Covid-19: The New Normal in Singapore Tji Tijan Chee, Singapore</p> <p>The Hidden Pandemic: Rising to meet Mental Health Challenges during Covid-19 Buvanawari P, Singapore <i>Chairperson:</i> <i>Li Yi</i></p>

11:30am – 12:30pm	<p style="text-align: center;">Symposium 2 Schizophrenia: from clinical heterogeneity to innovative treatment approaches</p> <p>Hypermethylation of RUFY1 associated with high risks of schizophrenia and poor treatment responses in Han Chinese Weihua Yue, China</p> <p>Frontal-posterior functional imbalance and aberrant function developmental patterns in schizophrenia Fei Wang, China</p> <p>The role of white blood cell counts in metabolic changes and clinical symptom improvement after antipsychotics in patients with schizophrenia: evidence from a large Chinese cohort Yamin Zhang, China</p> <p>Developing new drugs for schizophrenia: Mechanism study of fingolimod and a novel AMPA receptor positive allosteric modulator LT-102 as therapeutic agents for facilitating cognitive function in schizophrenia model Xueli Yu, China</p> <p><i>Chairperson: Tao Li, China</i></p>	<p style="text-align: center;">Special Session 1 (Sumitomo) Tx of bipolar depression: Lows are not forever</p> <p>Asian Perspective on Challenges in Managing Bipolar I Disorder (Bipolar Depression) Ya Mei Bai, Taiwan</p> <p>Navigating the Lows: Current Evidences on Pharmacological Treatment for Bipolar I Disorder (Bipolar Depression) Leslie Citrome, USA</p> <p><i>Chairpersons:</i> <i>Ya Mei Bai, Taiwan</i> <i>Leslie Citrome, USA</i></p>	<p style="text-align: center;">Symposium 11 Update on Treatment of Schizophrenia using Atypical Antipsychotics</p> <p>Optimizing Treatment for Patients with Schizophrenia Ahmad Hatim B Sulaiman, Malaysia</p> <p>Effect of Adjuvant Vitamin C on Brain-Derived Neurotrophic Factor (BDNF) Levels and Improvement of Negative Symptoms in Schizophrenic Patients Kristian Liaury, Indonesia</p> <p>Recent Trend in Neuropsychopharmacology in Japan Norio Yasui-Furukori, Japan</p> <p>Profiles of antipsychotic use among schizophrenia patients in Indonesia: Results from the REAP Study Andi Tanra, Indonesia</p> <p><i>Chairperson: Andi Tanra, Indonesia</i></p>
12:30pm – 13:30pm	<p>Lunch and Poster Viewing</p>	<p style="text-align: center;">Special Session 2 (Servier) Overcoming emotional blunting in the treatment of depression</p> <p>David Castle, Canada</p> <p><i>Chairperson: Roger Ho, Singapore</i></p>	
13:30pm- 15:00pm	<p style="text-align: center;">Symposium 3 REAP Bipolar Disorder and Mood Stabiliser Study: What we found and what we have learned</p> <p>Polypharmacy in Bipolar disorder: Findings from REAP Bipolar Disorder study Vie Cheong Thong, Malaysia</p> <p>Clinical use of mood stabilizers in REAP Study - Focus on clinical symptoms of bipolar disorder Isa Multazam Noor, Indonesia</p>	<p style="text-align: center;">Symposium 4 How do microglia contribute to psychiatric disorders? -immunological crosstalk between mind and body</p> <p>Multiple modes of stress-induced inflammation in the brain and periphery Tomoyuki Furuyashiki, Japan</p> <p>Thalamic microglial activation and cognitive impairment Shin-ichi Kano, USA</p> <p>Interaction between microglia and neurons: role in stress sensitivity and depression treatment</p>	

	<p>Clinical use of mood stabilizers in Asian patients: summary from REAP-BD and MS studies Pornjira Pariwatcharakul, Thailand</p> <p>Research on Asian Psychotropic Prescription Patterns on Minor Psychiatric Disorders: Focusing on Generalized Anxiety disorder, Obsessive Compulsive Disorder and Panic Disorder Lin Shih Ku, Thailand</p> <p><i>Chairperson:</i> Lin Shih Ku, Taiwan</p>	<p>Laura Maggi, Italy</p> <p>Epigenetics, neuroinflammation and aging: genome-wide DNA methylation of delirium Gen Shinozaki, USA</p> <p>Human blood-induced microglia-like (iMG) cells as a reverse translational research tool to clarify mind-brain-body interactions Takahiro A. Kato, Japan</p> <p><i>Chairpersons:</i> Takahiro Kato, Japan Tomoyuki Furuyashiki, Japan Cyrus Ho, Singapore</p>	
15:00pm – 16:30pm	<p style="text-align: center;">Meet Expert 2 (Otsuka) Advances in the understanding and management of treatment resistance in bipolar disorder</p> <p>Eduard Vieta, Spain</p> <p><i>Chairperson:</i> Yu Wei Lee, Singapore</p>	<p style="text-align: center;">Oral Presentation 1: Pain/Basic Science</p> <p>Differential roles of 5-HT3 and 5-HT7 receptors in acute pruriceptive processing in mice Yu Miyahara, Japan</p> <p>A gene genetically associated with herpes zoster or post-herpetic neuralgia has impacts on varicella-zoster virus-mediated fusogenic activity Seii Ohka, Japan</p> <p>Association between postoperative analgesia after major abdominal surgery and a single nucleotide polymorphism rs12496846 in the C3orf20 gene region, identified to be associated with postoperative analgesia after mandibular sagittal split ramus osteotomy Daisuke Nishizawa, Japan</p> <p>The oculomotor foraging task: a novel behavioral paradigm to evaluate multiple components of working memory Ryo Sawagashira, Japan</p> <p><i>Chairperson:</i> Gavin Dawe</p>	<p style="text-align: center;">Symposium 12: Guideline for Pharmacological Therapy of Schizophrenia by JSNP</p> <p>Introduction of the Guideline for Pharmacological Therapy of Schizophrenia Hiroyuki Uchida, Japan</p> <p>Implementing Evidence-Based Practices for People with Schizophrenia in Japan Kenji Sakuma, Japan</p> <p>Pharmacological treatment of relapse/recurrence in patients with schizophrenia Hikaru Hori, Japan</p> <p>Maintenance treatment of Schizophrenia Hiroyoshi Takeuchi, Japan</p> <p>Treatment resistance schizophrenia Ryota Hashimoto, Japan</p> <p><i>Chairperson:</i> Ryota Hashimoto</p>
16:30pm – 17:30pm	<p style="text-align: center;">Plenary 2 Evidence Based Mental Health in the Real World: Promises, Challenges and Future Directions</p> <p>Andrea Cipriani, United Kingdom</p> <p><i>Chairperson:</i> Roger Ho</p>		

Time	Virtual Auditorium 1	Virtual Auditorium 2	Virtual Auditorium 3
9:30 am – 11:00am	<p style="text-align: center;">Plenary 3 Artificial Intelligence in the Pharmacological Treatment of Psychiatric Conditions</p> <p>Roger McIntyre, Canada</p> <p><i>Chairperson:</i> <i>Kang Sim, Singapore</i></p>		<p style="text-align: center;">Special Session 3: Child and Adolescent Psychiatry</p> <p>Pharmacological Strategies in Complex ADHD Timothy E Wilens, USA</p> <p>Advanced psychopharmacologic treatment for Child and Adolescent with Autism Spectrum Disorder Joshi Gagan, USA</p> <p><i>Chairperson:</i> <i>John Wong, Singapore</i></p>
9.30am – 11:00am	<p style="text-align: center;">Symposium 5 Immune markers in psychiatric disorders</p> <p>Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression Roger Ho, Singapore</p> <p>Therapeutic strategy in schizophrenia by targeting neuroinflammation Kristian Liaury, Indonesia</p> <p>Immune markers in psychiatric disorders: leptin-modulated corticostriatal circuitry in bipolar I and bipolar II disorders Po See Chen, Taiwan</p> <p>Inflammatory markers and Mood Disorders: Proinflammatory Cytokine Dysregulation, Cognitive Dysfunction, and Reduced Gray Matter Volumes among Patients with Bipolar Disorder and Major Depressive Disorder Ya Mei Bai, Taiwan</p> <p><i>Chairperson:</i> <i>Ya Mei Bai, Taiwan</i></p>	<p style="text-align: center;">Symposium 6 Neuropsychopharmacology and mental health in COVID-19 pandemic</p> <p>Genetic association between COVID-19 and substance use disorders Shinya Kasai, Japan</p> <p>Using Psychotropic Drugs to Treat Long-Covid Syndrome Roger McIntyre, Canada</p> <p>A chain mediation model on COVID-19 symptoms and mental health outcomes in America, Asia and Europe Roger Ho, Singapore</p> <p>Feasibility and Effectiveness of Art therapies for improving health and well-being of children during COVID-19: A global synthesis Minh- Anh Le, USA</p> <p><i>Chairperson:</i> <i>Shinya Kasai, Japan</i></p>	

	<p>hyperprolactinemia: a network meta-analysis of randomized controlled trials Han Qi, China</p> <p>Meta-analysis of randomized, double-blind, placebo- controlled trials of melatonin in Alzheimer’s disease Yuan Yuan Wang, UK</p> <p>Efficacy and safety of traditional Chinese herbal medicine for antipsychotic-related constipation: a systematic review and meta-analysis of randomized controlled trials Wenwang Rao, China</p> <p>Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis Yikang Zhu</p> <p><i>Chairpersons:</i> Yu Tao Xiang, China Sim Kang, Singapore</p>		
15:00pm – 16:30pm	<p style="text-align: center;">Symposium 8</p> <p style="text-align: center;">Schizophrenia and depression research: state-of-the-art knowledge and the future</p> <p>Future of Psychiatry: Role of Technology Xin-Min Li, Canada</p> <p>Advances in psychotherapy/pharmacotherapy enhanced neuromodulation in treating major depressive disorder Yanbo Zhang, Canada</p> <p>TBC Yuan-Hwa Chou, Taiwan</p> <p>Pipeline Medications for Schizophrenia Lin Shih Ku</p> <p><i>Chairperson: Lin Shih Ku, Taiwan</i></p>	<p style="text-align: center;">Symposium 9</p> <p style="text-align: center;">Advances in computational neuropsychopharmacology – progress and challenges</p> <p>Oxytocin begets large-scale cooperation: A biobehavioral mechanism for the dynamic spread of cooperation in human social networks Yina Ma, China</p> <p>Brain networks under acute stress Rongjun Yu, Hong Kong</p> <p>Examining flexible decision-making in compulsive disorders and after pharmacological challenges using computational modelling Jonathan Kanen, UK</p> <p>Precision pharmaco-imaging: development and application of a neuroimaging-based fear signature Benjamin Becker, China</p> <p><i>Chairperson: Benjamin Becker</i></p>	
16:30pm – 16:40pm	<p style="text-align: center;">Closing remarks by Gavin Dawe</p> <p>Announcement of best oral presentation and poster awards</p>		